Exploring The Potential of Cytokine Therapies to Transform Cancer Treatment

In this exclusive interview, we welcome Caroline Loew, CEO of Mural Oncology, to discuss the potential of cytokine-based immunotherapies for cancer treatment. Additionally, we explore the transformative role of engineered cytokines, such as nemvaleukin, in oncology and delve into various topics related to Mural Oncology’s research and novel drug candidates in their pipeline.

Some of the main topics in this interview include:

• Given the transformative potential of cytokine-based immunotherapies in cancer treatment, could you elaborate on your strategic approach to advancing these therapies, particularly in cancers with currently limited treatment options?
• Mural Oncology has made significant advances in protein engineering to enhance cytokine therapy. Can you discuss the challenges and breakthroughs your team has encountered in engineering cytokines like nemvaleukin to optimize efficacy and reduce toxicity?
• Nemvaleukin alfa is a pivotal candidate in your pipeline, currently undergoing trials in conditions like platinum-resistant ovarian cancer and advanced melanoma. Could you share any updates or early findings from these trials?
• There are some exciting developments about IL-18 based therapy. What makes it a promising candidate for cancer therapy, and when do you plan to start clinical trials?
• What is your approach to combination therapies, particularly the integration of nemvaleukin with other treatment modalities like PD-1 inhibitors? What synergies are you exploring?
• Could you expand on the strategic importance of developing nemvaleukin as both a monotherapy and in combination with other drugs?

Please share your questions and comments with us throughout this webinar.